Breaking News
June 24, 2018 - Dying cancer cells make remaining glioblastoma cells more aggressive and therapy-resistant
June 24, 2018 - Researchers discover new type of cell that hinders formation of fat cells
June 24, 2018 - Scientists develop unique program to predict a form of Parkinson’s disease
June 24, 2018 - Adult Obesity Prevalence Varies With Level of Urbanization
June 24, 2018 - Picking an exercise boot camp
June 24, 2018 - Researchers outline a connection between subplate neurons and brain disorders
June 24, 2018 - Four cups of coffee a day shown to protect heart muscle
June 24, 2018 - ‘Antifreeze’ molecules may hold key to better treatments for brain injuries
June 24, 2018 - Opening onsite health clinics for workers can cut health care costs
June 24, 2018 - Glooko to demonstrate new version of diabetes management mobile application at ADA meeting
June 24, 2018 - Florida Teen First Human Case of Another Mosquito-Borne Virus
June 24, 2018 - Blood type O patients may have higher risk of death from severe trauma
June 24, 2018 - New studies on molecular and cellular proteomics
June 24, 2018 - Algorithm predicts dangerous low blood pressure during surgery
June 24, 2018 - Herpes may play role in pathogenesis of Alzheimer’s
June 24, 2018 - Inaccurate measurement of sodium intake may account for paradoxical results, study suggests
June 24, 2018 - Aquinnah Pharmaceuticals wins NINDS grant to advance novel therapies for ALS
June 24, 2018 - Study upends conventional view of opioid mechanism of action
June 24, 2018 - Floppy eyelids may be sign of sleep apnea, study finds
June 23, 2018 - Researchers highlight new nurse training model to address shortage of primary care
June 23, 2018 - New Olympus cellSens 2.1 speeds up image analysis
June 23, 2018 - Attitudes Among Obese Are Not Aligned With Healthy Living
June 23, 2018 - Early birds less prone to depression
June 23, 2018 - Scientists use novel approach to uncover how brain networks interact to make word-choice decisions
June 23, 2018 - Researchers discover shared genetic basis for psychiatric disorders
June 23, 2018 - Study shows fat cells increase in size and number upon exposure to fracking chemicals
June 23, 2018 - Water-limited landscapes can facilitate disease transmission
June 23, 2018 - Exercise May Ease Inflammation Tied to Obesity
June 23, 2018 - Is it their own fault?! How people judge the exclusion of others
June 23, 2018 - Researchers use advanced technology to identify proteomes of Th17 and iTreg cells
June 23, 2018 - Researchers develop low-cost plastic sensors to monitor wide range of health conditions
June 23, 2018 - Lipid-scrambling DNA enzyme outperforms naturally occurring counterpart, say researchers
June 23, 2018 - Apps for children should emphasize parent and child choice, researchers say
June 23, 2018 - Teenage girls report higher degree of daytime sleepiness than boys
June 23, 2018 - Protein Data Bank at Rutgers impacts research, education and drug discovery
June 23, 2018 - Study unravels new piece of information in the Huntington’s disease puzzle
June 23, 2018 - Scientists develop new device to test cancer drug combinations quickly and cheaply
June 23, 2018 - Neural Analytics wins CE Mark for NeuralBot System
June 23, 2018 - Infant omega-3 supplementation tied to decreased waist size
June 23, 2018 - Massive analysis of genomes reveals insights into genetic overlap among psychiatric diseases
June 23, 2018 - New therapeutic approach may delay neurodegeneration in rare genetic disease
June 23, 2018 - Broken shuttle protein may hinder learning in patients with brain disorders
June 23, 2018 - Study finds increase in daily cannabis use among American adults
June 23, 2018 - Researchers create electronic skin that brings back real sense of touch to prosthetic limbs
June 23, 2018 - FIRS: Guidance Offered for Protecting Youth From E-Cigarettes
June 23, 2018 - Scientists unravel molecular mechanisms of Parkinson’s disease
June 23, 2018 - When the Heart Stops, Drugs Often to Blame
June 23, 2018 - Scientists show that a key Parkinson’s biomarker can be identified in the retina
June 23, 2018 - Study finds factors underlying current rise in radicalization among European youth
June 23, 2018 - New study finds higher heart disease risk in bisexual men
June 23, 2018 - Coconut oil diet increases vitality, lifespan of fruit flies with peroxisomal disorder
June 23, 2018 - Jumping genes or transposons and their role in the genetic code
June 23, 2018 - The Current issue of “The view from here” is concerned with Therapeutics
June 23, 2018 - Abnormal lipid metabolism in fat cells predicts future weight gain and diabetes in women
June 23, 2018 - Alcohol problems linked to sex without condom use among black gay men
June 23, 2018 - DNA patterns in circulating blood cells can help identify spastic cerebral palsy
June 23, 2018 - Unsubstantiated health claims widespread within weight loss industry
June 23, 2018 - FDA grants marketing authorization for use of two catheter-based devices in hemodialysis patients
June 23, 2018 - An ingrown toenail not the same as a bypass
June 23, 2018 - Study suggests proteinuria lowering as important target in managing pediatric CKD
June 23, 2018 - Dynamic model helps make predictions about gut microbiome
June 23, 2018 - Research consortium wins £2.9 million to help tackle antibacterial resistance in Thailand
June 23, 2018 - Schizophrenia patients account for over 1 in 10 suicide deaths, study shows
June 23, 2018 - Overdose risk increases five-fold with concurrent opioid and benzodiazepine use
June 23, 2018 - FDA Alert: Kratom (mitragyna speciosa) powder products by Gaia Ethnobotanical: Recall
June 23, 2018 - Study highlights inadequate effort of health care insurers to combat opioid epidemic
June 23, 2018 - CDC chief asks for, and gets, cut to his record $375K pay
June 22, 2018 - Novel cellular pathway may clarify how arterial inflammation develops into atherosclerosis
June 22, 2018 - Pioneering exercise program improves physical, mental health of elderly people living in care homes
June 22, 2018 - Rutgers Cancer Institute educates childhood cancer survivors about late effects of treatment
June 22, 2018 - Study tests accuracy of device designed to detect heart dysfunction in childhood cancer survivors
June 22, 2018 - Study links annual haze with increased hospitalizations for respiratory problems
June 22, 2018 - Robotic surgery appears to be as effective as open surgery in treating bladder cancer
June 22, 2018 - Many Drugs Made Available Via FDA Expanded Access Programs
June 22, 2018 - Normal eye dominance is not necessary for restoring visual acuity in amblyopia
June 22, 2018 - Parent-Child Interaction Therapy can reduce depression rates in children
June 22, 2018 - Study provides insights into how components of different cells in the brain are altered
June 22, 2018 - Research does not confirm antidiabetic action of natural fatty acid derivatives
June 22, 2018 - Oxidative stress can be used against tumors to treat cancer
June 22, 2018 - Simple, cost-effective test may help improve early diagnosis of mild cognitive impairment
Factors ID’d That Predict RA Remission with Etanercept

Factors ID’d That Predict RA Remission with Etanercept

image_pdfDownload PDFimage_print

Action Points

  • Rheumatoid arthritis (RA) patients who were younger, had lower body mass index (BMI), better Health Assessment Questionnaire (HAQ) scores, and less baseine disease activity were most likely to achieve remission after combination etanercept (Enbrel) and methotrexate induction therapy, based on post hoc analysis of clinical trial data.
  • Note that the findings suggest that targeting sustained clinical remission in patients receiving full-dose combination etanercept-methotrexate therapy before considering dose or regimen changes may improve the likelihood that patients will remain in clinical remission.

Rheumatoid arthritis (RA) patients who were younger and who had lower body mass index (BMI), Health Assessment Questionnaire (HAQ) scores, and less disease activity at baseline were most likely to achieve remission after combination etanercept (Enbrel) and methotrexate induction therapy, a post hoc analysis of the PRESERVE trial found.

Patients who failed to achieve sustained remission with induction therapy and ones with worse disease activity and patient-reported outcomes soon after starting maintenance therapy were most likely to lose remission, reported Josef S. Smolen, MD, of the Medical University of Vienna, and colleagues.

“This result underscores and reinforces the current treat-to-target approach and the importance of adjusting treatment in patients who are not achieving the lowest levels of disease activity currently recommended in the American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) treatment guidelines, as it suggests that the depth and duration of response are relevant,” they wrote online in Arthritis Research & Therapy.

In 2013, the PRESERVE trial showed that after etanercept was withdrawn, etanercept-methotrexate combinations were more effective in maintaining low RA disease activity than methotrexate alone. In this post hoc analysis, the researchers aimed to identify potential predictive markers that induced remission or caused it to fail over time.

When PRESERVE was designed, the new, more stringent ACR and EULAR remission criteria had not been published. While Disease Activity Score in 28 joints (DAS28) <2.6 no longer defines remission, the authors used it in this analysis to be consistent with the primary manuscript, also looking at Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) remission values.

The PRESERVE trial studied adults with active RA who had moderate disease activity (DAS28>3.2 and ≤5.1 at baseline). All patients enrolled in the initial open-label period were treated for 36 weeks with etanercept 50 mg once weekly plus methotrexate.

At the start of the open-label period, 83% of patients were women, average age was 48, and mean DAS28, SDAI, and CDAI scores were 4.4, 19.1, and 17.8.

After 36 weeks, patients who achieved sustained low disease activity (an average DAS28≤3.2 from weeks 12 to 36 and DAS28≤3.2 at week 36) were randomized to continue weekly subcutaneous injections of etanercept 50 mg, reduce the etanercept dose to 25 mg, or withdraw etanercept and receive placebo injections, all with background methotrexate, for a 52-week double-blind period.

While similar proportions of patients treated with etanercept 50 mg and etanercept 25 mg maintained remission in the double-blind period, withdrawing etanercept resulted in a loss of remission in many patients.

Several continuous baseline factors appeared to predict DAS28, SDAI, and CDAI remission after 36 weeks. Lower baseline DAS28, SDAI, and CDAI, younger age, BMI under 30,and lower HAQ score were significant predictors of all three endpoints.

For all three treatments, the strongest predictors of loss of DAS28 remission included failure to achieve sustained remission with induction therapy (DAS28<2.6 at weeks 12, 20, 28, and 36), higher DAS28, SDAI, and CDAI at randomization and at 1 month, increase in DAS28, SDAI, and CDAI at 1 month, and increase in DAS28, CDAI, SDAI components and patient-reported outcomes at 1 month. SDAI and CDAI remission had similar predictors.

“The lower the DAS28, and thus the lower the residual disease activity level, the greater the likelihood of sustained response,” the researchers wrote, noting that predictors for sustained SDAI and CDAI remission “further support the conclusion of a better outcome with lower disease activity and maintenance of a good response at the time of withdrawal.”

“These findings may help guide clinicians’ decision-making as they treat patients to remission and beyond,” they added.

The PRESERVE trial and its analyses have several limitations. The study excluded patients with mild or severe disease activity or with certain comorbid diseases. Predictors of remission analyses were limited to data collected in the first 36-week period of the PRESERVE trial.

Because SDAI and CDAI remission were more stringent endpoints, with fewer patients achieving them than DAS28 remission, analyses about SDAI and CDAI remission loss had less power to detect differences than analyses about the loss of DAS28 remission.

This post-hoc analyis of the PRESERVE trial was sponsored by Pfizer.

Study authors disclosed relationships with AbbVie, BMS, MSD, Pfizer, Roche, Astra-Zeneca, Boehringer Ingelheim, Celgene, Celtrion, GSK, ILTOO, Janssen, Lilly, Novartis-Sandoz, Samsung, and UCB. Some authors were contractors or employees of Pfizer.

2018-01-21T15:00:00-0500

Tagged with:

About author

Related Articles